# Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

> **NCT03326336** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **GenSight Biologics** · enrollment: 10 (actual)

## Conditions studied

- Non-syndromic Retinitis Pigmentosa

## Interventions

- **COMBINATION_PRODUCT:** Gene therapy: GS030-DP AND Medical device: GS030-MD

## Key facts

- **NCT ID:** NCT03326336
- **Lead sponsor:** GenSight Biologics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-09-26
- **Primary completion:** 2027-10-26
- **Final completion:** 2027-10-26
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03326336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03326336, "Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03326336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*